Goodwin’s IP Litigation team achieved a victory for Celltrion, Inc. when the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) cancelled claims of U.S. Patent 8,591,897 in an inter partes review (IPR) filed by Celltrion. The ’897 patent relates to a method of treating breast cancer using certain chemotherapy agents in combination with trastuzumab, the active ingredient in Genentech’s biologic product Herceptin®. Celltrion is seeking to market a biosimilar version of Herceptin® in the United States.
Celltrion is a leading biopharmaceutical company, specializing in research, development and manufacture of biosimilar and innovative drugs.
The Goodwin team included associates Kevin DeJong and Josh Weinger and partner Elaine Blais.